CLEAR Outcomes Company Update Call: Detailed Results Discussion
22 févr. 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a conference call and webcast on Monday, March 6th, 2023 where Esperion Chief Medical Officer...
Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
21 févr. 2023 07h00 HE
|
Esperion Therapeutics, Inc.
– Landmark CLEAR Outcomes Trial Successfully Completed and Met the Major Adverse Cardiovascular Events (MACE-4) Primary Endpoint and Additional Key Secondary Endpoints; Additional Details in 11 Days...
Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC
20 févr. 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 20, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announces that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial will...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
13 févr. 2023 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on February 13, 2023, the Compensation Committee of Esperion’s Board of Directors granted six new...
Esperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023
07 févr. 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report fourth quarter and full year 2022 financial results before the open of the U.S. financial...
RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500
11 janv. 2023 11h00 HE
|
Esperion Therapeutics, Inc.
CONCORD, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- RFK Racing has announced that Esperion Therapeutics, a Michigan-based pharmaceutical company, has partnered with the team for a multi-year agreement...
Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results
08 janv. 2023 19h00 HE
|
Esperion Therapeutics, Inc.
– Based on the robustness of the CLEAR Outcomes data across primary and secondary endpoints, Company anticipates global regulatory submissions in 1H 2023 and believes it is entitled to receive...
CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC)
19 déc. 2022 16h15 HE
|
Esperion Therapeutics, Inc.
– Positive CLEAR Outcomes data to be presented as a Late-Breaking Clinical Trial (LBCT) at ACC.23/WCC on March 4, 2023 – – Bempedoic acid becomes the first ATP citrate lyase inhibitor and first oral...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
13 déc. 2022 18h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on December 9, 2022, the Compensation Committee of Esperion’s Board of Directors granted 2 new...
Esperion to Participate in January Investor Meetings
13 déc. 2022 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the Company plans to present at the J.P. Morgan 41st Annual Healthcare Conference as well as the...